secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K
Filed at:   2025-05-21T23:59:59+00:00
Accession:  0001641172-25-011842
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INVO Fertility Q1 2025 revenue up 4% but net loss widens to $17.4M on $14.6M impairment
--------------------------------------------------------------------------------

- Revenue $1.64M, +4% YoY; clinic revenue from consolidated centers +5% to $1.62M.
- Net loss of $17.4M vs $1.6M; includes $14.6M non-cash impairment on NAYA Therapeutics assets.
- Adjusted EBITDA loss widened to $(606,551) from $(427,467) in prior year.
- Company refocuses on fertility after April 2025 decision to divest majority stake in NAYA TX.
- CEO cites supportive policy shifts and aims for cash flow break-even through clinic expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000164117225011842/0001641172-25-011842-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000164117225011842/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-011842

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer